|
|
Blood, 1 November 2006, Vol. 108, No. 9, pp. 3161-3167.
Prepublished online as a Blood First Edition Paper on July 20, 2006; DOI 10.1182/blood-2005-01-026690.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes
Deirdre A. Hill,
Sophia S. Wang,
James R. Cerhan,
Scott Davis,
Wendy Cozen,
Richard K. Severson,
Patricia Hartge,
Sholom Wacholder,
Meredith Yeager,
Stephen J. Chanock, and
Nathaniel Rothman
From the Cancer Center and Department of Internal Medicine, University of New Mexico, Albuquerque, NM; Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, MD; Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; University of Iowa, Iowa City; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles; Karmanos Cancer Institute and Department of Family Medicine, Wayne State University, Detroit, MI; and Core Genotyping Facility, Advanced Technology Corporation, NCI, NIH, DHHS, Gaithersburg, MD.
Chromosomal translocations, insertions, and deletions are common early events in non-Hodgkin lymphoma (NHL) carcinogenesis, and implicated in their formation are endogenous processes involved in antigen-receptor diversification, such as V(D)J recombination. DNA repair genes respond to the double- and single-strand breaks induced by these processes and may influence NHL etiology. We examined 34 genetic variants in 19 genes within or related to 5 DNA repair pathways among 1172 cases and 982 matched controls who participated in a population-based NHL study in Los Angeles, Seattle, Detroit, and Iowa from 1998 to 2000. Cases were more likely than controls to have the RAG1 820 R/R (odds ratio [OR] = 2.7; 95% confidence interval [CI] = 1.4 to 5.0) than Lys/Lys genotypes, with evidence of a gene dosage effect (P trend < .001), and less likely to have the LIG4 (DNA ligase IV) 9 Ile/Ile (OR = 0.5; 95% CI = 0.3 to 0.9) than T/T genotype (P trend = .03) in the nonhomologous end joining (NHEJ)/V(D)J pathway. These NHEJ/V(D)J-related gene variants represent promising candidates for further studies of NHL etiology and require replication in other studies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma
- Kathryn Scott, Peter J. Adamson, Sharon L. Barrans, Lisa J. Worrillow, Eleanor V. Willett, and James M. Allan
Blood 2007 109: 5522-5523.
[Full Text]
[PDF]
-
NHL and genomic variability in RAG1 and BRCA2
- Deirdre A. Hill, Sophia Wang, Patricia Hartge, and Nathaniel Rothman
Blood 2007 109: 5523.
[Full Text]
[PDF]
-
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER Case-Control Study
- Unhee Lim, Sophia S. Wang, Patricia Hartge, Wendy Cozen, Linda E. Kelemen, Stephen Chanock, Scott Davis, Aaron Blair, Maryjean Schenk, Nathaniel Rothman, and Qing Lan
Blood 2007 109: 3050-3059.
[Abstract]
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
H. Yang, J. Gu, X. Lin, H. B. Grossman, Y. Ye, C. P. Dinney, and X. Wu
Profiling of Genetic Variations in Inflammation Pathway Genes in Relation to Bladder Cancer Predisposition
Clin. Cancer Res.,
April 1, 2008;
14(7):
2236 - 2244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Curry, D. Schulz, C. J. Guidos, J. S. Danska, L. Nutter, A. Nussenzweig, and M. S. Schlissel
Chromosomal reinsertion of broken RSS ends during T cell development
J. Exp. Med.,
October 1, 2007;
204(10):
2293 - 2303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Shen, M. P. Purdue, A. Kricker, Q. Lan, A. E. Grulich, C. M. Vajdic, J. Turner, D. Whitby, S. Chanock, N. Rothman, et al.
Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia
Haematologica,
September 1, 2007;
92(9):
1180 - 1185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Scott, P. J. Adamson, S. L. Barrans, L. J. Worrillow, E. V. Willett, and J. M. Allan
RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma
Blood,
June 15, 2007;
109(12):
5522 - 5523.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Novik, J. J. Spinelli, A. C. MacArthur, K. Shumansky, P. Sipahimalani, S. Leach, A. Lai, J. M. Connors, R. D. Gascoyne, R. P. Gallagher, et al.
Genetic Variation in H2AFX Contributes to Risk of Non-Hodgkin Lymphoma
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2007;
16(6):
1098 - 1106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Lim, S. S. Wang, P. Hartge, W. Cozen, L. E. Kelemen, S. Chanock, S. Davis, A. Blair, M. Schenk, N. Rothman, et al.
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER Case-Control Study
Blood,
April 1, 2007;
109(7):
3050 - 3059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Goldin and S. L. Slager
Familial CLL: Genes and Environment
Hematology,
January 1, 2007;
2007(1):
339 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
